Skip to main content

conglomerates

Luxury

LVMH’s Watch Unit Takes Minority Stake in La Joux-Perret

The move deepens LVMH’s partnership with the high-end Swiss watch movement and component manufacturer.

Luxury

LVMH’s Watch Unit Takes Minority Stake in La Joux-Perret

The move deepens LVMH’s partnership with the high-end Swiss watch movement and component manufacturer.


Beauty

Shiseido Cuts Forecast, Announces New 2030 Strategy and Leadership

The Japanese conglomerate’s sales dipped to a nine month low in its latest earnings, which accompanied sweeping changes to leadership and the unveiling of its newest action plan.

Beauty

Shiseido Cuts Forecast, Announces New 2030 Strategy and Leadership

The Japanese conglomerate’s sales dipped to a nine month low in its latest earnings, which accompanied sweeping changes to leadership and the unveiling of its newest action plan.


Beauty

Novo Nordisk Bows Out of Metsera Takeover Battle

The Ozempic maker’s shares rose after Novo withdrew from a $10 billion takeover battle with Pfizer over obesity drug developer Metsera.

Beauty

Novo Nordisk Bows Out of Metsera Takeover Battle

The Ozempic maker’s shares rose after Novo withdrew from a $10 billion takeover battle with Pfizer over obesity drug developer Metsera.


Luxury

Is China’s Luxury Market Ready to Rebound?

The short answer is yes — but it won’t soon return to its pre-pandemic growth rates. After two years of turbulence, the market remains shaky, and brands will need to earn every sale.

Luxury

Is China’s Luxury Market Ready to Rebound?

The short answer is yes — but it won’t soon return to its pre-pandemic growth rates. After two years of turbulence, the market remains shaky, and brands will need to earn every sale.


Beauty

Kao Sales Lift 3.5% Against Cosmetics Business Reset

The Japanese conglomerate and Bioré owner’s latest earnings show early gains from its new strategy to drive beauty growth.

Beauty

Kao Sales Lift 3.5% Against Cosmetics Business Reset

The Japanese conglomerate and Bioré owner’s latest earnings show early gains from its new strategy to drive beauty growth.


Beauty

Pfizer Loses Legal Bid to Block Novo’s Metsera Offer

A judge denied Pfizer’s request to temporarily block Novo Nordisk’s $10 billion bid to acquire the obesity startup Metsera Inc., saying the US pharmaceutical company’s objections to the deal don’t warrant a delay.

Beauty

Pfizer Loses Legal Bid to Block Novo’s Metsera Offer

A judge denied Pfizer’s request to temporarily block Novo Nordisk’s $10 billion bid to acquire the obesity startup Metsera Inc., saying the US pharmaceutical company’s objections to the deal don’t warrant a delay.


Beauty

Coty Stares Into a Gucci-less Void

L’Oréal is set to take over the coveted Gucci license in a few short years, but losing a key brand is just one of the US conglomerate’s woes.

Beauty

Coty Stares Into a Gucci-less Void

L’Oréal is set to take over the coveted Gucci license in a few short years, but losing a key brand is just one of the US conglomerate’s woes.


Beauty

Coty Revenues Drop 6%, Forecasts Second-Quarter Sales at Top End of Guidance

The American cosmetics giant said demand for core fragrances from Chloé and Hugo Boss had insulated it from a further decline, and expects a return to growth in the second half of its fiscal year.

Beauty

Coty Revenues Drop 6%, Forecasts Second-Quarter Sales at Top End of Guidance

The American cosmetics giant said demand for core fragrances from Chloé and Hugo Boss had insulated it from a further decline, and expects a return to growth in the second half of its fiscal year.


Beauty

Novo Cuts Outlook Once Again, Highlighting Obesity Struggles

The Ozempic and Wegovy maker pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs, underscoring the urgency facing its new chief executive.

Beauty

Novo Cuts Outlook Once Again, Highlighting Obesity Struggles

The Ozempic and Wegovy maker pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs, underscoring the urgency facing its new chief executive.


Beauty

What Next for Kenvue’s Beauty Brands?

The future of big-name brands like Neutrogena, Clean & Clear and Aveeno, which bring more than $4 billion a year in sales, is less clear under its new ownership by the tissue and feminine care giant Kimberly-Clark.

Beauty

What Next for Kenvue’s Beauty Brands?

The future of big-name brands like Neutrogena, Clean & Clear and Aveeno, which bring more than $4 billion a year in sales, is less clear under its new ownership by the tissue and feminine care giant Kimberly-Clark.


Series

Kimberly-Clark to Buy Tylenol Owner Kenvue in $40 Billion Deal

Kimberly-Clark Corp. agreed to buy Kenvue Inc. in a cash and stock deal that values the consumer-health company that owns brands like Tylenol at about $40 billion.

Series

Kimberly-Clark to Buy Tylenol Owner Kenvue in $40 Billion Deal

Kimberly-Clark Corp. agreed to buy Kenvue Inc. in a cash and stock deal that values the consumer-health company that owns brands like Tylenol at about $40 billion.


Beauty

Novo Nordisk Offers $9 Billion Unsolicited Bid for Obesity Drug Maker Metsera

The Danish pharmaceutical company, which makes Ozempic and Wegovy, made a surprise offer for the US firm after Pfizer acquired it for $4.9 billion in September.

Beauty

Novo Nordisk Offers $9 Billion Unsolicited Bid for Obesity Drug Maker Metsera

The Danish pharmaceutical company, which makes Ozempic and Wegovy, made a surprise offer for the US firm after Pfizer acquired it for $4.9 billion in September.